The impact of the CYP2D6 gene polymorphism on the risk of pemphigoid

被引:11
|
作者
Rychlik-Sych, Mariola [1 ]
Baranska, Malgorzata [1 ]
Wojtczak, Anna [1 ]
Skretkowicz, Jadwiga [1 ]
Zebrowska, Agnieszka [2 ]
Waszczykowska, Elzbieta [2 ]
机构
[1] Med Univ Lodz, Dept Pharmacogenet, Lodz, Poland
[2] Med Univ Lodz, Dept Dermatol & Venereol, Lodz, Poland
关键词
SYSTEMIC-LUPUS-ERYTHEMATOSUS; AUTOIMMUNE BULLOUS DISEASES; PARKINSONS-DISEASE; COVALENT BINDING; DRUG-REACTIONS; KERATINOCYTES; OXIDATION; SKIN; METABOLITES; EXPRESSION;
D O I
10.1111/ijd.12967
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
BackgroundStudies concerning the etiopathogenesis of numerous diseases emphasize the involvement of genetically determined impairments of xenobiotic metabolism. Nowadays, more attention has been drawn to the role of cytochrome P450 and its isoenzymes in the course of dermatological diseases, including pemphigoid, the most frequently occurring autoimmune bullous disease, whose etiopathogenesis has not been completely elucidated. AimThe aim of the study was to find out whether there was any relationship between the CYP2D6 gene polymorphism and the development of bullous pemphigoid (BP). Material and methodsThe study included 221 subjects, 71 patients with BP, and 150 healthy volunteers constituting a control group. The identification of CYP2D6 (CYP2D6*1, CYP2D6*3, CYP2D6*4) gene alleles was performed using the polymerase chain reaction-fragment length polymorphism method. ResultsA higher frequency of the CYP2D6*3/CYP2D6*4 genotype was observed in patients with BP (P=0.0033) than in controls. The relative risk of developing BP expressed with the odds ratio was nearly four times higher in subjects in whom the presence of the CYP2D6*3 allele was detected (odds ratio 3.8; P=0.0234). ConclusionThe study results may suggest the impact of CYP2D6 gene polymorphism (A2637 deletion) on a higher prevalence of bullous pemphigoid.
引用
收藏
页码:1396 / 1401
页数:6
相关论文
共 50 条
  • [1] The Impact of the CYP2D6 "Enhancer" Single Nucleotide Polymorphism on CYP2D6 Activity
    Dinh, Jean C.
    Boone, Erin C.
    Staggs, Vincent S.
    Pearce, Robin E.
    Wang, Wendy Y.
    Gaedigk, Roger
    Leeder, James Steven
    Gaedigk, Andrea
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2022, 111 (03) : 646 - 654
  • [2] Significance of the genetic polymorphism of CYP2D6 in patients with bullous pemphigoid
    Rychlik-Sych, Mariola
    Baranska, Malgorzata
    Wojtczak, Anna
    Skretkowicz, Jadwiga
    Zebrowska, Agnieszka
    Waszczykowska, Elzbieta
    [J]. PHARMACOLOGICAL REPORTS, 2015, 67 : 37 - 38
  • [3] PNAT AND CYP2D6 GENE POLYMORPHISM IN EPILEPTIC PATIENTS
    BORLAK, JT
    HARSANY, V
    SCHNEBLE, H
    HAEGELE, KD
    [J]. BIOCHEMICAL PHARMACOLOGY, 1994, 48 (09) : 1717 - 1720
  • [4] Genetic polymorphism of CYP2D6 and lung cancer risk
    Shaw, GL
    Falk, RT
    Frame, JN
    Weiffenbach, B
    Nesbitt, JC
    Pass, HI
    Caporaso, NE
    Moir, DT
    Tucker, MA
    [J]. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 1998, 7 (03) : 215 - 219
  • [5] Clinical impact of CYP2D6 polymorphism on the therapy with antidepressants and antipsychotics -: case reports of CYP2D6 poor metabolisers
    Lohmann, PL
    Frahnert, C
    Grasmäder, K
    Hiemke, C
    Laux, G
    Rao, ML
    [J]. PSYCHOPHARMAKOTHERAPIE, 2003, 10 (01): : 35 - 38
  • [6] Statin therapy correlated CYP2D6 gene polymorphism and hyperlipidemia
    Li, Juyi
    Wang, Xiufang
    Zhang, Zhaoqing
    Zou, Jili
    Chen, Yonggang
    Wang, Xiong
    Wu, Jinhu
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2014, 30 (02) : 223 - 228
  • [7] Impact of CYP2D6 polymorphism on tamoxifen therapy: where are we?
    Huber-Wechselberger, Ariana E.
    Niedetzky, Paul
    Aigner, Irene
    Haschke-Becher, Elisabeth
    [J]. WIENER MEDIZINISCHE WOCHENSCHRIFT, 2012, 162 (11-12) : 252 - 261
  • [8] Impact of CYP2D6 Genetic Polymorphism on Tramadol Pharmacokinetics and Pharmacodynamics
    Siew Hua Gan
    Rush Ismail
    Wan Aasim Wan Adnan
    Wan Zulmi
    [J]. Molecular Diagnosis & Therapy, 2007, 11 (3) : 171 - 181
  • [9] Impact of CYP2D6 genetic polymorphism on tramadol pharmacokinetics and pharmacodynamics
    Gan, Siew Hua
    Ismail, Rusli
    Adnan, Wan Aasim Wan
    Zulmi, Wan
    [J]. MOLECULAR DIAGNOSIS & THERAPY, 2007, 11 (03) : 171 - 181
  • [10] Genetic polymorphism of CYP2D6 and lung cancer risk.
    Arnaud, L
    Gallegos, MP
    Gomez, BC
    Morgan, G
    Flores, MC
    Rangel, H
    Zuiga, GM
    [J]. AMERICAN JOURNAL OF HUMAN GENETICS, 2001, 69 (04) : 270 - 270